InnovAge Holding Corp. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended December 31, 2021; filed February 9, 2022. Amounts below are in U.S. dollars, generally millions unless stated otherwise.
Business context and reporting period
InnovAge operates PACE programs, providing coordinated medical and support services to frail seniors under capitated arrangements with Medicare, Medicaid, and other payors. It served approximately 7,050 participants through 18 centers in five states. The company bears responsibility for participants’ healthcare costs. Sacramento became consolidated in January 2021, affecting comparability with the prior-year period.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2021 | Three months ended Dec. 31, 2020 | Six months ended Dec. 31, 2021 | Six months ended Dec. 31, 2020 |
|---|---|---|---|---|
| Total revenue | $175.4 | $157.3 | $348.4 | $309.9 |
| Operating income (loss) | $3.0 | $20.5 | $14.6 | $(17.6) |
| Net income (loss) | $1.1 | $9.6 | $8.7 | $(40.2) |
| Net income (loss) attributable to InnovAge | $1.3 | $9.7 | $9.0 | $(40.0) |
| Adjusted EBITDA, non-GAAP | $14.8 | $22.6 | $33.0 | $45.7 |
Second-quarter revenue increased 11.5%, while operating income fell to $3.0 million. Operating margin was approximately 1.7%, compared with 13.1% in the prior-year quarter. For the six-month period, Adjusted EBITDA margin declined to 9.5% from 14.8%, and center-level contribution margin was $83.7 million, or 24.0% of revenue, versus $84.7 million, or 27.3%.
Capitation revenue rose 11.8% in the quarter and 12.7% for the six months. Management attributed six-month growth to member-month increases of 7.7% and capitation-rate increases of 4.6%. In the quarter, external provider costs rose 21.1%, faster than revenue; management cited higher cost per participant, delayed care returning after the pandemic, Omicron-related effects, and higher housing rates. Cost of care rose 12.7% in the quarter. Corporate, general and administrative expense rose 81.1% in the quarter, including public-company, compliance, legal, executive severance and recruiting costs. The prior-year six-month comparison included substantial Apax transaction and option-cancellation expenses, explaining the reported year-over-year decline in G&A.
Six-month operating cash flow was $31.6 million, compared with cash used of $0.7 million a year earlier. Investing activities used $13.7 million, including $11.7 million for property and equipment and $2.0 million for an investment; financing activities used $3.0 million. Cash and cash equivalents were $216.3 million at December 31, with an additional $2.2 million of restricted cash. Total assets were $558.0 million and total liabilities $189.6 million.
Debt principal was approximately $75.5 million: $73.1 million under the term loan and $2.4 million under a convertible loan. The term-loan rate was 1.84%; no revolver borrowings were outstanding, with $100 million of stated capacity subject to letters of credit, covenants and other conditions. The company reported covenant compliance. Management said cash and operating cash flows were expected to meet operating and capital needs for at least the next 12 months. Lease commitments and planned investment, including potential center development, remain liquidity demands.
Material changes, outlook, and risks
- CMS and state agencies suspended new enrollments at the Sacramento center in September 2021 and at Colorado centers in December 2021 over audit findings concerning participant care. The suspensions remain pending remediation and agency approval. Colorado also faces a required consultant and a paid $10,000 penalty; Sacramento’s corrective action plan was accepted and is being monitored. Enrollment restrictions constrain census growth and contribution margin.
- CMS’s audit of the Albuquerque center identified preliminary care-related deficiencies in November 2021; validation was ongoing, and further sanctions were possible. California suspended state assurances for planned new PACE centers pending Sacramento remediation. In February 2022, Kentucky notified InnovAge it no longer intended to enter a provider agreement.
- Management identified growth through existing centers, new centers and acquisitions as strategic opportunities, but gave no quantified financial guidance. It expects expenses to rise in absolute dollars to support growth and public-company requirements. It also cited persistent labor, supply-chain and medical-cost pressures, and noted that the ultimate financial impact of COVID-19 is not reliably estimable.
- A Colorado Medicaid False Claims Act investigation was ongoing; in February 2022, the DOJ issued a related federal investigative demand covering several states. The company said it was cooperating and could not predict outcomes. A putative shareholder class action filed in October 2021 alleges misleading IPO statements. The filing states that adverse outcomes could entail costs, penalties or operational restrictions.
- The filing reports a nonmaterial restatement of June 30, 2021 balances, reclassifying $17.0 million of redeemable noncontrolling interests from permanent equity to temporary equity. Management concluded disclosure controls were effective and reported no material internal-control changes in the quarter.
- CEO Maureen Hewitt resigned effective January 1, 2022; President Patrick Blair became CEO. The filing identifies transition and execution as risks.
Most important facts for investors to verify
- Current status, scope and duration of the Colorado and Sacramento enrollment suspensions; corrective-action milestones and any additional sanctions.
- Progress and potential consequences of the Colorado and DOJ investigations, the shareholder lawsuit, and the Albuquerque audit.
- Enrollment, member months and per-participant medical costs, particularly whether provider-cost growth moderates relative to capitation revenue.
- Adjusted EBITDA and margin trends, including the definition and adjustments used in this non-GAAP measure; the filing’s narrative contains an inconsistent six-month Adjusted EBITDA figure, while its reconciliation reports $33.0 million.
- Cash generation, planned capital spending, lease commitments, borrowing capacity and compliance with credit-facility covenants.